SM
LEXX icon

Sabby Management’s Lexaria Bioscience LEXX Stock Holding History

Sabby Management’s Portfolio LEXX Stock Details LEXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,165,144
Closed -$1.01M – 55
2025
Q2 		$1.01M Buy
+1,165,144
New +$1.34M 1.84% 9

Other funds holding LEXX

ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
BAM
Byrne Asset Management Kingston, New Jersey $185M AUM 41.05% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sabby Management's LEXX Position: Q3 2025 in Review

Sabby Management sold out of Lexaria Bioscience (LEXX) in Q3 2025, closing a stake of 1,165,144 shares — an estimated $1.01M sold.

Sabby Management first reported a position in LEXX in Q2 2025 and held it in 1 quarter. The position peaked at $1.01M in Q2 2025. 25 funds tracked by Wall St. Rank hold LEXX as of Q3 2025.

  • Sabby Management reported no remaining Lexaria Bioscience position as of Q3 2025 after selling out during the quarter.
  • Sabby Management sold 1,165,144 Lexaria Bioscience shares in Q3 2025, an estimated $1.01M.
  • Sabby Management first reported a position in Lexaria Bioscience in Q2 2025 and held it in 1 quarter.
  • Sabby Management's Lexaria Bioscience position peaked at $1.01M in Q2 2025.
  • 25 funds tracked by Wall St. Rank held Lexaria Bioscience as of Q3 2025.

Based on Sabby Management's 13F filing for Q3 2025, filed 14 Nov 2025.